million inhabitants, adjusted rates were: 0.96 for Brazil, 0.98 for Mexico, 8.6 for Uruguay, 0.53 for Argentina, 1.27 for Cuba and 0.08 for Colombia (Figure 1 ). Despite the fact that the exact number of transplants done in Latin America is not known precisely, there seems to be a correlation between the transplant rates and the rates of publication. The two largest countries, Brazil and Mexico, have similar ratios, whereas Uruguay, one of the smallest countries, has the highest ratio. Figure 2 depicts cumulative publications per year. Overall, 53 reports were in Bone Marrow Transplantation, 12 in Biology of Blood and Marrow Transplantation, 31 in Revista Brasileira de Hematología y Hemoterapia and 273 in other journals. In all, 63.7% were published in journals with an impact factor 41 and 49.1% in journals with an impact factor 43. Most reports detailing transplant activity in a country are case reports or describe modifications to reduce costs. There were few collaborative studies.
The first bone marrow transplant (BMT) in Latin America was performed 430 years ago and since then several countries have started transplant programs. [1] [2] [3] Recently, the Latin American Group of Bone Marrow Transplantation (LABMT) was founded as a member society of the Worldwide Network for Blood and Marrow Transplantation. 2 Objectives of the LABMT include a registry of transplants and of publications. On the basis of published data on optimal transplant rates in Europe and North America, we calculated o 10% of the ideal numbers of transplants are currently done in Latin America. 1, 3 Argentina, Mexico and Brazil have the largest activity and despite annual increases, most transplants remain HLA-identical sibling and autotransplants. 1 Challenges are cost, donor availability, numbers of transplant centers and lack of expertise. These issues need to be addressed for further progress in the region. 1 To obtain information about the Latin American BMT publications, the Dissemination and Education Committee of the LABMT contacted all board members representing the Hematology and BMT Societies within Latin America asking for papers published in peer-reviewed journals by Latin American authors or coauthors about clinical or research hematopoietic cell transplant activity performed within our countries, between 1990 and 2014. We identified 369 papers published in peer-reviewed journals in that period by authors or coauthors based in Latin America: 187 from Brazil, 116 from Mexico, 26 from Uruguay, 22 from Argentina, 14 from Cuba and 4 from Colombia. No response was obtained from other Latin American countries (see Supplementary Appendix). By dividing the number of publications between the population in million inhabitants, adjusted rates were: 0.96 for Brazil, 0.98 for Mexico, 8.6 for Uruguay, 0.53 for Argentina, 1.27 for Cuba and 0.08 for Colombia (Figure 1 ). Despite the fact that the exact number of transplants done in Latin America is not known precisely, there seems to be a correlation between the transplant rates and the rates of publication. The two largest countries, Brazil and Mexico, have similar ratios, whereas Uruguay, one of the smallest countries, has the highest ratio. Figure 2 
In all, 63.7% were published in journals with an impact factor 41 and 49.1% in journals with an impact factor 43. Most reports detailing transplant activity in a country are case reports or describe modifications to reduce costs. There were few collaborative studies.
Despite limitations and obvious biases in data collection, this information highlights activities of physicians performing transplants in Latin America in the hope that it will promote additional activity and support increased cooperation between countries and transplant centers within and outside our region. Following the World Health Organization guiding principles on transplantation it has to be mentioned that the data collection and analysis are integral parts of the therapy and hence, establishment of a registry should be a mandatory obligation. 4 
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